Pulse nav.journalClub Tendances Explorer Chercheurs

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Politique de confidentialité

Accueil Explorer nav.journalClub Tendances

⌘+K

Anti-CD19 CAR T cell therapy for refractory SLE-ITP | Synapse

March 22, 2026Open Access

Anti-CD19 CAR T cell therapy for refractory SLE-ITP

Key Points

Evaluate the effectiveness of anti-CD19 CAR T cell therapy for patients with refractory immune thrombocytopenic purpura associated with systemic lupus erythematosus.
Supported by the Chinese National Key Technology R&D Program and other funding sources.
Involved patients with refractory immune thrombocytopenic purpura.
Analyzed treatment outcomes and safety.
Showed improved treatment responses in patients with refractory conditions.
Safety profile indicated a manageable adverse events rate.

Abstract

This study was supported by the Chinese National Key Technology R the CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005); and National High Level Hospital Clinical Research Funding (2025-PUMCH-D-001, 2022-PUMCH-B-013, D-009). This study was also funded and supported by Juventas Cell Therapy Ltd.

Read Full Paperexternally

Like

Bookmark

Share

View Full Paper

Like

Bookmark

Share

View Full Paper

Cite This Study

Li et al. (Sun,) studied this question.

synapsesocial.com/papers/69bf8641f665edcd009e8cf0 https://doi.org/https://doi.org/10.1016/j.medj.2026.101039